We built NeuroBlu, the gold standard for real-world data for behavioral health, to bridge the gap between research and care and improve patient outcomes.
Yesterday, Holmusk's VP of #RWE, Nadia Lipunova, joined Daniel Joyce, Gary Leeming, and Chair @profbuchan for a dynamic discussion around how the digital revolution and data-driven technologies can reshape #brainhealth, held by @GlobalBrainHea1. @info_TGHN https://t.co/ey0zFxGKQd
Very interesting panel conversation with our founder and @Mersey_Care chief executive Joe Rafferty looking at how we can use AI and machine learning to prevent suicide. Incredibly important in a world increasingly led by technology. Read more here: https://t.co/GG2kGsgyKf #SuicidePrevention #ZSIS5
Yesterday at #HLTHEurope, our Founder & CEO Nawal Roy spoke on the panel, The other burn rate - Why founders experience burnout, and how to fix it, joined by Vijay Barathan, Optum Ventures, and @bbgfrei, @rootine_co. Thank you to @HLTHEvent for hosting this dynamic discussion!
We are proud to be named as a real-world data company in the Pharma AI market map in @CBinsights’ 2024 Tech Trends in Healthcare & Lifesciences report. We have a unique passion for driving change in mental health and leverage #NLP-enriched #RWD to accelerate progress and care.
10 DAYS LEFT! FREE Clinical Exchange Workshop
🗓️28th June, 2pm GMT
Join @profbuchan, Prof Daniel Joyce, Gary Leeming, and Nadia Lipunova as they share their expertise.
Register👇
https://t.co/kfxSd5jsaX
Last week, Holmusk spent a dynamic 2 days connecting with leaders and innovators in healthcare at #NHSConfedExpo in Manchester. Holmusk is proud to be exploring innovative ways to support healthcare delivery in the UK. Learn more about @confedexpo at https://t.co/qu809N7uqv
The @DukeMargolis Real-World Evidence Collaborative has published a new white paper, Regulatory Fit-for-Purpose Considerations for Patient-Generated Health Data. Holmusk is proud to be a contributor to this paper and a collaborative member. #RWD#RWE https://t.co/DlI7FE3gg5
Next week, our CEO and Founder Nawal Roy will speak at the Future of Mental Healthcare Summit about state-of-the-art innovations in behavioral health measurement--and how those innovations drive improved outcomes. #mentalhealth#RWD Learn more or register: https://t.co/w9bJImftOj
Excited that our Founder and CEO Nawal Roy had the chance to share his insights in this report from @DigitalHealthNY! Check out the report below, or read more of his thoughts about reducing #mentalhealth stigma on the blog: https://t.co/CNqW3Pe3Zx
The Q1 2023 NY Healthcare Innovation Report is live & provides an in-depth look at digital health funding, trends, and insights from the first three months of the year. Download the report now: https://t.co/EyPM5yJMLV #digitalhealth
New publication: An analysis of #RWD from our #NeuroBlu Database explores a question that has been investigated in several #cllinicaltrials about a treatment for major depressive disorder. Do findings from routine care reflect the study setting? Find out: https://t.co/IBwWLUq7OF
At #EPA2023, we presented research on clinical instability, enabled by #RWD within our #NeuroBlu Database and led by @uniofoxford senior research fellow & Holmusk collaborator @maximetaquet.
The study was also published in @thelancetpsych:
https://t.co/q8IhQPVbFr
Get the breakdown on latest #NeuroBlu-enabled research published in @TheLancetPsych from lead author @MaximeTaquet! #RWE
Or read more here: https://t.co/Zd044ke7yP
This research builds on important work on mood instability by @matthewrbroome, @PsychMarwaha, #MariaFaurholtJepsen, #KateSaunders etc.
It was made possible by @holmusk which has fine-grained deidentified EHR data from 1.4 million people. https://t.co/n6sNkbGKeI 7/7
New in @TheLancetPsych: Analysis of #RWD from our #NeuroBlu Database, led by @MaximeTaquet, shows that instability is consistently an important predictor of psychiatric hospitalization risk across diagnoses, ages, & sex: https://t.co/wuNnVJ7SM1
Our Founder and CEO, Nawal Roy, reflects on the recently announced strategic investment from @Veradigm and what this means for Holmusk's future: https://t.co/QFCdGWxkD7
#RWE#behavioralhealth
Exciting news! @Veradigm has invested in @holmusk, leading their $45 million Series B fundraising round. Holmusk will leverage this investment to continue its rapid expansion of its flagship offering, the NeuroBlu Database ➡️ https://t.co/LS9knQZszu
Look out for even more exciting work from @holmusk following this impressive series B fundraising round led by @Veradigm. The time to invest in mental health is now!
We are delighted to share that @Veradigm has invested in Holmusk, leading our $45 million Series B fundraising round. We look forward to continuing our work in building a leading #RWD source to advance research and care for behavioral health conditions.
Thanks to @DukeMargolis' RWE Collaborative for inviting us to speak to fellow members during a two-day workshop on patient subgroups! Read more about why #RWE is needed to find the best treatment for everyone: https://t.co/UWQzNOM8F5